-
Hybribio’s Chloroquine Phosphate Gel Cleared for Clinical Trial on High-Risk HPV Infections
•
Hybribio Limited (SHE: 300639), a Guangdong-based pharmaceutical company, has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for its chloroquine phosphate gel, a patented pharmaceutical preparation in China. The gel, designed for topical administration, is intended to reduce systemic exposure and is formulated…
-
Hybribio Ltd Secures NMPA Approval for α-Thalassemia Genotyping Detection Kit
•
Hybribio Ltd (SHE: 300639), a Guangdong-based provider of nucleic acid molecular diagnostic products, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its α-thalassemia genotyping detection kit. The kit, which utilizes PCR and flow cytometry technology, is designed for qualitative detection of 10…
